Triple agonist

A triple agonist is a single molecule engineered to activate three hormone receptors at once. In obesity medicine that means GLP-1, GIP and glucagon — the combination in retatrutide, the most advanced drug of this kind. No triple agonist is FDA-approved.

The logic is an extension of what dual agonists demonstrated. GLP-1 suppresses appetite; GIP appears to add something on top of that; glucagon contributes from a different direction entirely, increasing energy expenditure and mobilizing liver fat rather than reducing intake. Three levers, three mechanisms.

The phase 2 evidence is striking. In 338 adults with obesity, retatrutide produced average weight change at 48 weeks of −17.1% at 4 mg, −22.8% at 8 mg and −24.2% at 12 mg, against −2.1% on placebo. For comparison, tirzepatide’s phase 3 trial reported −20.9% at its top dose over 72 weeks. Retatrutide reached a larger number in less time, in a smaller and earlier-stage study.

That last clause is where the caution lives. Phase 2 trials are short, small and enrolled from a narrower population, and effects routinely shrink in phase 3. The retatrutide trial also reported dose-dependent increases in heart rate peaking at 24 weeks, and dose-related gastrointestinal adverse events partially mitigated by a lower starting dose. More receptors is not a free lunch.

For patients, the practical meaning of this term today is defensive. FDA states that retatrutide cannot lawfully be used in compounding, is not a component of any approved drug, and has not been found safe and effective for any condition — and it has warned telehealth companies marketing it directly to consumers. A “triple agonist” for sale online is a warning sign. Our retatrutide review and naming explainer unpack the hype.